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Abstract To study the hypothesis that a delay in the
diagnosis of paediatric brain tumours results in decreased
survival outcome probability, we compared the prediagnostic
period of 315 brain tumour patients (median age 6.7 years,
range, 0 to 16 years) with progression-free and overall
survival. The median prediagnostic symptomatic interval
was 60 days (range, 0 to 3,480 days), with a median parental
delay of 14 days (range, 0 to 1,835 days) and a median
doctor’s delay of 14 days (range, 0 to 3,480 days). The
prediagnostic symptomatic interval correlated significantly
with the patient age, tumour histology, tumour location and
year of diagnosis, but not with gender. We then grouped the
patients according to histology (low-grade glioma [n=77],
medulloblastoma [n=57], high-grade glioma [n=40], cranio-
pharyngioma [n=27], ependymoma [n=20] and germ cell
tumours [n=18]). Contrary to common belief, long prediag-
nostic symptomatic interval or long doctor’s delay did not
result in decreased survival outcome probability in any of
these groups. The effect of tumour biology on survival seems
to be dominant and overwhelms any possible opposing effect
on survival of a delay in diagnosis.
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Introduction
As a group, brain tumours are the most common solid
tumours in children [9]. They differ from primary central
nervous system tumours occurring in adults not only in
histology, localisation, management and prognosis, but also
in clinical presentation [14]. At the onset of illness, the
nature of neurological and systemic dysfunction is often
non-specific and variable, and relates not only to the site of
origin of the tumour, but also to the child’s age and
developmental level [20]. The diagnosis of brain tumours
poses difficulties and this is sometimes reflected in long
prediagnostic symptomatic intervals (PSI) [3, 4, 8, 13, 15,
16, 18, 22, 23]. The better availability of computed
tomography (CT) and magnetic resonance imaging (MRI)
since the 1990s has resulted in shorter doctor’s delay [3].
However, the median PSI of a recently described cohort of
200 patients diagnosed between 1988 and 2001 was still
2.5 months (range, 1 day to 120 months) [23]. Understand-
ably, parents frequently raise the question as to whether an
earlier diagnosis could have been made and, if so, whether
the “delay” adversely affects prognosis. Recent reports
describe the symptomatology of paediatric brain tumour
cohorts [3, 22, 23], but information on the potential
influence of PSI and doctor’s delay on prognosis is scant.
The present study was undertaken to study the common
belief that a delay in the diagnosis of paediatric brain
tumours results in decreased survival outcome probability.
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Patients and methods
A retrospective study was undertaken on children up to the
age of 16 years with primary brain tumours, admitted
consecutively to the University Children’s Hospital of
Zurich, Switzerland, from January 1980 to December
2004. The clinical signs and symptoms of part of this
series (n=252) have been reported previously [3]. Medical
case notes, referral letters, neurosurgical records, histopa-
thology reports, follow-up and survival outcomes were
reviewed by two independent investigators (K.K. and M.
D.). The PSI was defined as the interval between the onset
of signs/symptoms and the time of diagnosis by MRI, CT or
other imaging techniques. The PSI was subdivided into an
interval between symptom onset and the first medical
consultation (parental delay), and an interval between the
first medical consultation and diagnosis by CT, MRI or
other imaging techniques (doctor’s delay). Discrepancies in
the PSI were noted for 32 patients. These cases were re-
examined together with the last author, and a consensus
was reached.
Statistical analyses
Since most data were non-normally distributed, medians
and interquartile ranges (IQR) were calculated for descrip-
tive statistics, and non-parametric exact methods were used
in the analytical statistics. In order to assess potential
associations between the patient characteristics and delays,
the Wilcoxon-Mann-Whitney test was used for binary
variables, the Kruskal-Wallis test for categorical variables
and the Jonckheere-Terpstra test for continuously measured
variables divided into ordered categories before analysis.
Overall survival (OS) was defined as the probability of
survival, with only death as the event; children who were
alive were censored at their last follow-up. Progression-free
survival (PFS) was defined as the probability of being alive
and free of progression/relapse; death and progression/
relapse were considered as events. For survival analysis, the
Kaplan-Meier estimate and its 95% confidence intervals
(95% CI) were calculated. Age at diagnosis, PSI and the
doctor’s delay were categorized into four groups, each
according to their quartiles before analysis, since a linear
association between these delay times and outcome could
not been assumed. The log-rank test was used to detect
Table 1 Location and histology of the 315 brain tumours examined in
this study
Location and tumour histology Number of tumours %
Infratentorial 136 43
Medulloblastoma 57 18
Low-grade cerebellar glioma 31 10
Brainstem glioma 19 6
Ependymoma 11 3
Other 12 4
Tumours of unknown histology 6 2
Supratentorial hemispheric 103 33
Low-grade glioma 29 9
High-grade glioma 18 6
Choroid plexus tumour 7 2
Ependymoma 8 3
Primitive neuroectodermal tumours 7 2
Oligodendroglioma 3 1
Other 27 9
Tumours of unknown histology 4 1
Supratentorial midline 76 24
Craniopharyngioma 27 9
Germ cell tumour 17 5
Low-grade glioma 14 4
Primitive neuroectodermal tumours 2 1
Other 11 3
Tumours of unknown histology 5 2
Fig. 1 a Cumulative distribution of the prediagnostic symptomatic
interval (PSI) for 315 paediatric patients with brain tumours. b
Cumulative distribution of the doctor’s delay for 234 patients, where
medical charts permitted subdividing the PSI into an interval between
symptom onset and the first medical consultation (parental delay), and
an interval between the first medical consultation and diagnosis by
computed tomography (CT), magnetic resonance imaging (MRI) or
other imaging techniques (doctor’s delay)
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differences in survival between different groups of patients.
Two-sided tests were used throughout, and P-values below
0.05 were considered to be significant. StatXact 6 (Cytel
Software Corp., Cambridge, MA, USA) was used for the
exact non-parametric tests and S-PLUS 6.0 (Insightful
Corp., Seattle, WA, USA) was used for the survival
analyses and graphics.
Results
Patient and tumour characteristics
Three hundred and fifteen patients with a primary brain
tumour were admitted to the University Children’s Hospital
of Zurich, Switzerland, between January 1980 and December
2004. The tumour characteristics of these patients are
summarised in Table 1. They are comparable to those of
larger series [14]. Therefore, the present cohort can be
considered as adequately representative. The median age at
diagnosis for all patients was 6.7 years (range, 0.0 to
16.0 years; IQR, 3.0 to 10.5 years). One hundred and
eighty-five (59%) patients were male and 130 (41%) were
female. Tumour location was infratentorial in 136 (43%) and
supratentorial in 179 (57%) patients. Diagnoses were
established by the histological assessment of a tumour
specimen obtained at surgery in 274 (87%) patients and by
typical imaging findings in 26 (8%) patients (e.g. diffuse
intrinsic pontine glioma). In 15 (5%) patients with large
tumours and poor general condition, no biopsy was
undertaken and the histology remains unknown. The median
follow-up time for all patients was 3.4 years (range, 0.0 to
25.3 years).
Prediagnostic symptomatic interval
The median PSI of all patients was 60 days (range, 0 to
3,480 days; IQR, 21 to 180 days), with a median parental
delay of 14 days (range, 0 to 1,835 days; IQR, 0 to 46 days)
and a median doctor’s delay of 14 days (range, 0 to
3,480 days; IQR, 1 to 69 days) in the 234 (74%) patients
where this distinction was possible. Figure 1a shows the
overall cumulative distribution of PSI (n=315). Only 112
(36%) of the 315 brain tumours were diagnosed within
30 days from the onset of signs/symptoms. PSI was 31–
60 days in 62 (20%) patients, 61–180 days in 75 (24%)
Table 2 Prediagnostic symptomatic interval (PSI), parental delay and doctor’s delay (median and interquartile range [IQR]) in relation to age at
diagnosis, gender, histology, tumour location and year of diagnosis
PSI (days) Parental delay (days) Doctor’s delay (days)
Age at diagnosis JT=4.83, P<0.001 JT=2.23, P=0.025 JT=1.50, P=0.13
- Up to 4 years (n=100) 31 (14–62) 5 (0–27) 10 (1–49)
- 4 to 8 years (n=92) 63 (29–180) 21 (2–51) 14 (0–103)
- 8 to 12 years (n=62) 79 (33–270) 21 (0–48) 29 (6–66)
- ≥12 years (n=61) 106 (30–219) 11 (0–101) 20 (1–173)
Gender WMW=1.44, P=0.15 WMW=0.55, P=0.58 WMW=1.57, P=0.12
- Female (n=130) 60 (21–180) 14 (0–49) 21 (2–120)
- Male (n=185) 53 (21–150) 14 (0–44) 13 (0–60)
Histology KW=36.09, P<0.001 KW=15.1, P=0.017 KW=13.83, P=0.030
- Ependymoma (n=20) 30 (9–60) 5 (0–8) 5 (2–40)
- Medulloblastoma (n=57) 36 (21–60) 20 (3–40) 6 (0–30)
- Germ cell tumour (n=18) 39 (19–216) 14 (0–40) 14 (0–39)
- High-grade glioma (n=40) 49 (21–120) 10 (0–20) 13 (4–47)
- Low-grade glioma (n=77) 142 (42–195) 29 (3–86) 38 (2–148)
- Craniopharyngioma (n=27) 210 (81–445) 38 (4–135) 39 (7–338)
Location KW=9.47, P=0.008 KW=6.57, P=0.039 KW=2.85, P=0.24
- Infratentorial (n=136) 45 (23–124) 17 (2–42) 10 (0–43)
- Supratentorial hemisphere (n=103) 60 (15–180) 7 (0–30) 13 (1–120)
- Supratentorial midline (n=76) 98 (30–360) 21 (0–75) 25 (1–180)
Year of diagnosis JT=2.11, P=0.034 JT=0.57, P=0.57 JT=1.28, P=0.20
- 1980 to 1984 (n=66) 60 (30–210) 10 (0–30) 30 (4–165)
- 1985 to 1989 (n=51) 90 (30–202) 8 (0–56) 25 (0–96)
- 1990 to 1994 (n=61) 49 (21–175) 14 (0–46) 12 (0–60)
- 1995 to 1999 (n=59) 65 (28–180) 26 (0–90) 12 (0–70)
- 2000 to 2004 (n=78) 42 (17–118) 14 (1–37) 9 (2–49)
JT=Jonckheere-Terpstra statistic, exact P-value calculated; WMW=Wilcoxon-Mann-Whitney statistic, exact P-value calculated; KW=Kruskal-
Wallis statistic, exact P-value calculated.
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patients, 181–365 days in 31 (10%) patients and >365 days
in 35 (11%) patients.
The cumulative distribution of the doctor’s delay is
shown in Fig. 1b. The doctor’s delay was 0 days in 57
(24%) patients, 1–30 days in 81 (35%) patients, 31–60 days
in 35 (15%) patients, 61–180 days in 33 (14%) patients,
181–365 days in 14 (6%) patients and >365 days in 14
(6%) patients. The doctor’s delay, thus, exceeded 30 days in
96 (41%) of 234 patients. There was a non-significant trend
that doctor’s delays were longer compared with parental
delays (Wilcoxon signed-rank statistic, 1.51, P=0.15).
The age at diagnosis was significantly associated with
PSI, which was shorter in younger children (see Table 2).
This was mainly due to a shorter parental delay in younger
children, while doctor’s delay was not significantly associ-
ated with age at diagnosis. There was no association,
however, of gender with any of the three delay measures.
Tumour histology was also found to correlate with PSI.
Aggressive fast-growing tumours (e.g. medulloblastoma,
germ cell tumours and high-grade gliomas) had a shorter
PSI compared with slow-growing tumours (e.g. low-grade
gliomas and craniopharyngiomas; Table 2). The tumour
location was significantly associated with both PSI and
parental delay, with supratentorial midline tumours having
longer delays than supratentorial hemispheric (e.g. cases
presenting monosymptomatically with focal seizures) and
infratentorial tumours. During the study period of 25 years,
there was a statistically significant decrease in the PSI. This
was mainly due to a decrease in the doctor’s delay, which
might be explained by the improved availability of non-
invasive imaging techniques. At the Children’s Hospital of
Zurich, CT was introduced in 1982 and MRI in 1986. The
parental delays of the six most frequent brain tumours did
not change significantly over time.
Survival probability
The progression-free and overall survival of the 315
patients are summarised in Fig. 2. The estimated 5-year
and 10-year OS rates were 73% (95% CI, 68 to 79%) and
71% (66 to 77%), respectively. The estimated 5-year and
10-year PFS rates were 53% (95% CI, 47 to 59%) and 48%
(42 to 55%), respectively.
Survival probability according to PSI
Progression-free and overall survival according to PSI are
summarised in Fig. 3. In the group with the longest PSI
(≥180 days, n=83), the survival probability was the highest
(10-year OS 86% and PFS 61%), followed by the group
with PSI <20 days (n=66; 10-year OS 71% and PFS 49%),
the group with PSI 60–179 days (n=82; 10-year OS 66%
and PFS 43%) and the group with PSI 20–59 days (n=84;
10-year OS 61% and PFS 39%). These differences were
significant for both OS (P<0.001) and PFS (P=0.029).
Survival probability according to doctor’s delay
Progression-free and overall survival according to doctor’s
delay are summarised in Fig. 4. The survival probability
was highest in the group with the longest doctor’s delay
(≥70 days, n=59, 10-year OS 78% and PFS 60%), followed
by the group without any doctor’s delay (<1 day, n=57;
10-year OS 67% and PFS 53%), the group with doctor’s delay
14–70 days (n=62; 10-year OS 67% and PFS 40%) and the
group with doctor’s delay 1–14 days (n=56; 10-year OS 64%
and PFS 49%). However, these differences were not
statistically significant (P=0.24 for OS and P=0.64 for PFS).
Survival probability of histological subgroups according
to PSI and doctor’s delay
We then grouped the patients according to histology (low-
grade glioma [n=77], medulloblastoma [n=57], high-grade
Fig. 2 a, b Estimated survival of 315 paediatric patients with brain
tumours. Kaplan-Meier curves show the probability of overall survival
(OS, a) and progression-free survival (PFS, b)
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glioma [n=40], craniopharyngioma [n=27], ependymoma
[n=20] and germ cell tumours [n=18]) and repeated the
analyses. Despite the fact that both PSI and doctor’s delay
were significantly different between these subgroups
(Table 2), shorter PSI or shorter doctor’s delay did not
result in better survival outcome probabilities in any of
them (data are shown for the two largest groups, low-grade
glioma and medulloblastoma; Table 3).
Discussion
Parents frequently tend to blame the primary care doctor for
a “delay in the diagnosis” of a brain tumour and questions
are raised as to whether an earlier diagnosis could have
been made and, if so, whether the “delay” has adversely
affected the prognosis. Therefore, in the current study, we
tested the hypothesis that paediatric brain tumour patients
with a shorter PSI have a better prognosis. Indeed, lay
people may think that the child who is diagnosed with a
brief history of symptoms/signs is more likely to have a
smaller brain tumour that is easier to resect. The prognostic
value of extensive tumour resection, which is controversial
with regard to malignant brain tumours in adults, has been
confirmed for a variety of childhood brain tumours,
including medulloblastoma, supratentorial primitive neuro-
ectodermal tumours, ependymoma and astrocytoma [2, 15,
17, 24, 25].
The PSI correlated significantly with the patient age,
tumour histology, tumour location and year of diagnosis.
This is in accordance with the literature [5, 16, 23]. Age
differences in PSI may be attributed to age-related differences
in the occurrence of tumour characteristics, such as brain
tumour symptoms and tumour location relative to the
tentorium, to differences in the tumour biology and to
differences in medical care.
Contrary to common belief, the PSI correlated inversely
with the progression-free and overall survival probability.
Our findings are in accordance with the previously reported
results of a smaller group of paediatric brain tumour
patients (n=28; [19]) and the results of Halperin et al [11].
Fig. 4 a, b Estimated survival of 234 paediatric brain tumour
patients, where medical charts permitted subdividing the PSI into a
parental and a doctor’s delay. Kaplan-Meier curves show the
probability of OS (a) and PFS (b) in relation to the duration of the
Fig. 3 a, b Estimated survival of 315 paediatric patients with brain
tumours in relation to the duration of the PSI. Kaplan-Meier curves
show the probability of OS (a) and PFS (b)
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Analysing 122 medulloblastoma patients, they found that
the PSI correlated inversely with metastatic stage at the
time of presentation. Although not tested formally in their
study, it can be assumed that patients with longer PSI had
not only lower metastatic stages, but also had higher
survival probability, because the metastatic stage is probably
the most important clinical risk factor in medulloblastoma [1,
7, 12, 21, 25].
This suggests that, often, it is the biology of the disease
that is the most important determinant for PSI and survival
probability. Some rapidly growing aggressive brain tumours
call attention to themselves more readily than slowly growing
tumours. Perhaps the more slowly growing tumours allow the
patient to adapt to the increase in intracranial pressure and
impingement on normal tissue more readily than to a rapidly
growing mass [6, 10, 11].
The doctor’s delay did correlate with tumour histology,
but not with the progression-free or overall survival
probability. This is also in contrast to common belief and
has potential legal implications. Alleged delay in diagnosis
is a common plaintiff’s assertion in cancer-related malprac-
tice suits. It is a fact that the more aggressive tumours tend
to be diagnosed after a shorter duration of symptoms than
less malignant tumours: this makes it difficult to cite the
long duration of symptoms, by itself, as a significant factor
in support of the argument that, “if only the diagnosis had
been made more quickly,” then the patient would have had
a better prognosis.
We believe that this study of a large series of children
with brain tumours represents the first analysis of the
relationships between PSI, doctor’s delay and survival
outcome probability. Clearly, this study has limitations.
The numbers of patients in each histological category are
small, the categories are not homogenous in terms of
localisation and biology, and the treatment used over a
relatively long period of time has not been uniform. As
analysis relied on a retrospective review of medical records,
it was not possible to assess the reliability with which the
data regarding symptom onset and the division of symptoms
into that occurring before and after medical advice was
recorded. However, the results do indicate that the age at
presentation and histology are determinants for PSI, and that
a short PSI is not necessarily related with better survival
outcome probability.
Table 3 Survival probabilities
(proportion in percentage
and 95% confidence interval
[CI]) according to PSI and
doctor’s delay
χ2 =log-rank statistic, 3
degrees of freedom
10-year OS 10-year PFS
All tumours (n=315) χ2=16.4, P<0.001 χ2=9.0, P=0.029
- PSI <20 days (n=66) 71 (59–85) 49 (37–64)
- PSI 20–59 days (n=84) 61 (50–73) 39 (28–54)
- PSI 60–179 days (n=82) 66 (55–80) 43 (32–60)
- PSI >180 days (n=83) 86 (78–95) 61 (50–74)
Tumours with known doctor’s delay (n=234) Χ2=4.2, P=0.24 χ2=1.7, P=0.64
- Doctor’s delay <1 day (n=57) 67 (55–81) 53 (41–68)
- Doctor’s delay 1–14 days (n=56) 64 (51–79) 49 (35–67)
- Doctor’s delay 15–70 days (n=62) 67 (53–83) 40 (26–60)
- Doctor’s delay >70 days (n=59) 77 (65–90) 60 (47–75)
Low-grade glioma (n=77) Χ2=2.5, P=0.48 χ2=3.3, P=0.35
- PSI <20 days (n=10) 100 58 (31–100)
- PSI 20–59 days (n=13) 92 (79–100) 92 (79–100)
- PSI 60–179 days (n=26) 76 (52–100) 50 (27–92)
- PSI >180 days (n=28) 94 (83–100) 63 (45–88)
Low-grade glioma with known doctor’s delay (n=58) Χ2=2.4, P=0.50 χ2=0.6, P=0.90
- Doctor’s delay <1 day (n=14) 100 76 (56–100)
- Doctor’s delay 1–14 days (n=9) 100 83 (58–100)
- Doctor’s delay 15–70 days (n=15) 74 (46–100) 53 (25–100)
- Doctor’s delay >70 days (n=20) 82 (60–100) 70 (52–94)
Medulloblastoma (n=57) Χ2=1.1, P=0.77 χ2=1.0, P=0.79
- PSI <20 days (n=12) 75 (54–100) 56 (34–94)
- PSI 20–59 days (n=27) 56 (40–80) 33 (19–59)
- PSI 60–179 days (n=14) 54 (33–90) 24 (5–100)
- PSI >180 days (n=4) 50 (19–100) 25 (5–100)
Medulloblastoma with known doctor’s delay (n=49) Χ2=1.8, P=0.60 χ2=1.3, P=0.72
- Doctor’s delay <1 day (n=16) 60 (39–91) 38 (19–75)
- Doctor’s delay 1–14 days (n=13) 39 (18–85) 23 (8–71)
- Doctor’s delay 15–70 days (n=15) 57 (36–91) 31 (12–81)
- Doctor’s delay >70 days (n=5) 50 (19–100) 25 (5–100)
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Instead of analysing the age at diagnosis, PSI and the
doctor’s delay by Spearman’s correlation, we deliberately
chose a method of analysis based on quartile grouping,
since, primarily, it cannot be assumed that the association of
delay with outcome is a linear one. As Figs. 2 (for PSI) and
4 (for doctor’s delay) demonstrate for the whole set of
patients, as does Table 3 for some important subgroups, this
assumption would clearly have been wrong. Since there is
no linear association between delay and outcome, we
deliberately chose to perform log-rank tests of outcomes
between subgroups of patients instead of performing Cox
regression analysis.
Future studies are needed that prospectively analyse
more homogeneous (histological and therapeutic) groups of
brain tumour patients. It still remains to be tested whether
long delays in diagnosis are associated with higher risks of
perioperative morbidity and, therefore, reduced quality of
life. Whilst a child might still survive with a brain tumour
diagnosed over a prolonged symptom interval, there may be
considerable impairment of cognitive function due to
prolonged hydrocephalus or other tumour-related brain
damage.
Independent of current and future study results, early
diagnosis remains a high priority. Patients with biologically
aggressive tumours are likely to profit from an early start of
anti-neoplastic therapy, and patients with slow growing
tumours might be salvaged from irreparable functional
deficits. Furthermore, a prolonged diagnostic delay is
associated with the high burden of uncertainty for the
families involved.
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